Cargando…

Plasma Lipocalin 2 in Alzheimer’s disease: potential utility in the differential diagnosis and relationship with other biomarkers

BACKGROUND: Lipocalin-2 is a glycoprotein that is involved in various physiological and pathophysiological processes. In the brain, it is expressed in response to vascular and other brain injury, as well as in Alzheimer’s disease in reactive microglia and astrocytes. Plasma Lipocalin-2 has been prop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hermann, Peter, Villar-Piqué, Anna, Schmitz, Matthias, Schmidt, Christian, Varges, Daniela, Goebel, Stefan, Bunck, Timothy, Lindemann, Hanna, Bogner, Carla, Santana, Isabel, Baldeiras, Inês, Riggert, Joachim, Zerr, Inga, Llorens, Franc
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8759265/ https://www.ncbi.nlm.nih.gov/pubmed/35027079 http://dx.doi.org/10.1186/s13195-021-00955-9

Ejemplares similares

Plasma YKL-40 in the spectrum of neurodegenerative dementia
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Cerebrospinal fluid lipocalin 2 as a novel biomarker for the differential diagnosis of vascular dementia
por: Llorens, Franc, et al.
Publicado: (2020)

Diagnostic and prognostic value of plasma neurofilament light and total-tau in sporadic Creutzfeldt-Jakob disease
por: Zerr, Inga, et al.
Publicado: (2021)

Detection of Cerebrospinal Fluid Neurofilament Light Chain as a Marker for Alpha-Synucleinopathies
por: Canaslan, Sezgi, et al.
Publicado: (2021)

Baseline Cerebrospinal Fluid α-Synuclein in Parkinson’s Disease Is Associated with Disease Progression and Cognitive Decline
por: Emdina, Anna, et al.
Publicado: (2022)

Cerebrospinal fluid neurogranin as a new player in prion disease diagnosis and prognosis
por: Villar-Piqué, Anna, et al.
Publicado: (2019)

Evaluation of Human Cerebrospinal Fluid Malate Dehydrogenase 1 as a Marker in Genetic Prion Disease Patients
por: Zerr, Inga, et al.
Publicado: (2019)

Optimization of the Real-Time Quaking-Induced Conversion Assay for Prion Disease Diagnosis
por: Zerr, Inga, et al.
Publicado: (2020)

Progress in CSF biomarker discovery in sCJD
por: Llorens, Franc, et al.
Publicado: (2016)

Application of an in vitro-amplification assay as a novel pre-screening test for compounds inhibiting the aggregation of prion protein scrapie
por: Schmitz, Matthias, et al.
Publicado: (2016)

Cerebrospinal Fluid Biomarkers of Alzheimer's Disease Show Different but Partially Overlapping Profile Compared to Vascular Dementia
por: Llorens, Franc, et al.
Publicado: (2017)

Total and Phosphorylated Cerebrospinal Fluid Tau in the Differential Diagnosis of Sporadic Creutzfeldt-Jakob Disease and Rapidly Progressive Alzheimer’s Disease
por: Hermann, Peter, et al.
Publicado: (2022)

Effect of the micro-environment on α-synuclein conversion and implication in seeded conversion assays
por: Candelise, Niccolo, et al.
Publicado: (2020)

CSF nonphosphorylated Tau as a biomarker for the discrimination of AD from CJD
por: Ermann, Natalia, et al.
Publicado: (2018)

Interlaboratory validation of cerebrospinal fluid α-synuclein quantification in the diagnosis of sporadic Creutzfeldt-Jakob disease
por: Kruse, Niels, et al.
Publicado: (2018)

Increased C-X-C Motif Chemokine Ligand 12 Levels in Cerebrospinal Fluid as a Candidate Biomarker in Sporadic Amyotrophic Lateral Sclerosis
por: Andrés-Benito, Pol, et al.
Publicado: (2020)

Sporadic Creutzfeldt-Jakob Disease among Physicians, Germany, 1993–2018
por: Hermann, Peter, et al.
Publicado: (2020)

Cerebrospinal Fluid Mitochondrial DNA in Rapid and Slow Progressive Forms of Alzheimer’s Disease
por: Podlesniy, Petar, et al.
Publicado: (2020)

Regulation of human cerebrospinal fluid malate dehydrogenase 1 in sporadic Creutzfeldt-Jakob disease patients
por: Schmitz, Matthias, et al.
Publicado: (2016)

Application of real-time quaking-induced conversion in Creutzfeldt–Jakob disease surveillance
por: Hermann, Peter, et al.
Publicado: (2023)

Diagnostic accuracy of cerebrospinal fluid biomarkers in genetic prion diseases
por: Schmitz, Matthias, et al.
Publicado: (2022)

TREM2 expression in the brain and biological fluids in prion diseases
por: Diaz-Lucena, Daniela, et al.
Publicado: (2021)

Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non-rapidly progressive Alzheimer’s disease
por: Herden, Janne Marieke, et al.
Publicado: (2023)

Correction: Comparative evaluation of clinical and cerebrospinal fluid biomarker characteristics in rapidly and non‑rapidly progressive Alzheimer’s disease
por: Herden, Janne Marieke, et al.
Publicado: (2023)

Genetic Variants Associated with the Age of Onset Identified by Whole-Exome Sequencing in Fatal Familial Insomnia
por: Thüne, Katrin, et al.
Publicado: (2023)

Diagnostic Accuracy of Prion Disease Biomarkers in Iatrogenic Creutzfeldt-Jakob Disease
por: Llorens, Franc, et al.
Publicado: (2020)

Characteristic CSF Prion Seeding Efficiency in Humans with Prion Diseases
por: Cramm, Maria, et al.
Publicado: (2014)

MicroRNA Alterations in the Brain and Body Fluids of Humans and Animal Prion Disease Models: Current Status and Perspectives
por: Kanata, Eirini, et al.
Publicado: (2018)

The Road to Personalized Medicine in Alzheimer’s Disease: The Use of Artificial Intelligence
por: Silva-Spínola, Anuschka, et al.
Publicado: (2022)

The role of cellular prion protein in lipid metabolism in the liver
por: Arora, Amandeep Singh, et al.
Publicado: (2020)

Subtype and Regional-Specific Neuroinflammation in Sporadic Creutzfeldt–Jakob Disease
por: Llorens, Franc, et al.
Publicado: (2014)

Prospective CERAD Neuropsychological Assessment in Patients With Multiple System Atrophy
por: Maass, Fabian, et al.
Publicado: (2022)

Stability and Reproducibility Underscore Utility of RT-QuIC for Diagnosis of Creutzfeldt-Jakob Disease
por: Cramm, Maria, et al.
Publicado: (2015)

Doxycycline in early CJD: a double-blinded randomised phase II and observational study
por: Varges, Daniela, et al.
Publicado: (2017)

Rapidly progressive dementias — aetiologies, diagnosis and management
por: Hermann, Peter, et al.
Publicado: (2022)

Immune responses in rapidly progressive dementia: a comparative study of neuroinflammatory markers in Creutzfeldt-Jakob disease, Alzheimer’s disease and multiple sclerosis
por: Stoeck, Katharina, et al.
Publicado: (2014)

Cellular Prion Protein (PrP(c)) and Hypoxia: True to Each Other in Good Times and in Bad, in Sickness, and in Health
por: Ramljak, Sanja, et al.
Publicado: (2016)

Tear Lipocalin and Lipocalin-Interacting Membrane Receptor
por: Glasgow, Ben J.
Publicado: (2021)

Role of different recombinant PrP substrates in the diagnostic accuracy of the CSF RT-QuIC assay in Creutzfeldt-Jakob disease
por: Da Silva Correia, Susana Margarida, et al.
Publicado: (2022)

Clinical validation of the Lumipulse G cerebrospinal fluid assays for routine diagnosis of Alzheimer’s disease
por: Leitão, Maria João, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_nvtq8rvvoj874f4acvjpg6v1nn